S260
Clinical - Breast
ESTRO 2026
(left) and recurrence (right)
received EBRe-RT at the LMU and TUM university hospitals between 2010 and 2024 was performed. Subsequently all patients were contacted and prospectively followed-up with a clinical examination and QoL questionnaires (BREAST-Q and EORTC QOL- C30). Results: At time of LRRBC, the average patient age was 64.6 (± 12) years, 76.8% were HR-positive, 11.6% Her2-positive and 13.3% triple negative. 49.7% were diagnosed as rpT1a-c (49.7%) and 53% as rpNx/rpN0.The preferred fractionation regimen both for initial- and EBRe-RT was 50.4 Gy at 1.8 Gy over 28 fractions with a median interval of 130 months (range: 113–430) between both treatments. The median total dose of primary radiotherapy was 53.4 Gy (±7.19 Gy), while it was 47.7 Gy (±5.72 Gy) at EBRe-RT. For details regarding therapy changes between both treatments see figure 1.EBRe- RT had an acceptable acute toxicity with only 4.9% grade 3 acute side effects (mainly dermatitis) and no grade 4 acute side effects. After a median follow up (FU) period of 32 months (range 0-236 months) we observed chronical grade 3 toxicity in 7.7% of the patients and one case of grade 4 toxicity (anterior myocardial infarction). During the FU period the OS was 80.1%, and recurrence was reported as followed: 10.5% developed local recurrence, 13.3% LRRBC and 27.6% distant metastases (see figure 2). From 52 patients who completed the EORTC QOL-C30 the median QoL was rated 5 (scale 1-7) and according to BREAST-Q the median psychosocial well-being was 4 (scale 1-5). 48.2% were “very” or “rather satisfied” with the appearance of the breast (median 3, scale 1-4). Conclusion: This is the largest study on EBRe-RT in breast cancer so far indicating that EBRe-RT is safe with acceptable acute and late toxicity. Further analysis will focus on optimal patient selection for EBRe-RT and optimal
Figure 2: Kaplan-Meier curve of the local-failure-free survival since EBRe-RT Keywords: re-irradiation, breast-cancer-recurrence
Digital Poster 1853 Efficacy and safety of re-irradiation in breast cancer bone metastasis Erald Karaulli 1 , Fatjona Kraja 2 , Helidon Nina 2 1 Oncology service, Mother Teresa university Hospital of Tirana, Tirana, Albania. 2 Oncology service, Mother Teresa University Hospital of Tirana, Tirana, Albania Purpose/Objective: To assess the clinical efficacy and safety of re- irradiation for bone metastases in patients with breast cancer, focusing on symptom relief, response rates, and treatment tolerance. Material/Methods: A retrospective analysis was conducted on 50 breast cancer patients who received 3 Dimensional Conformal Radiotherapy (3DCRT) for painful bone metastases and underwent 3DCRT re-irradiation at the same sites between 2021 and 2025. Treatment response was assessed as complete (CR), partial (PR), or no response (NR), and toxicity graded by CTCAE v5.0. Results: The median age of patients was 62.8 years (range 42– 83). The first course of radiotherapy consisted of 20 Gy in 5 fractions in 54%, 30 Gy in 10 fractions in 22%, and 8 Gy in a single fraction in 24% of cases, corresponding to a BED3range of 29.3–60 Gy. The initial treatment achieved high rates of symptom control, with 70% of patients obtaining CR and 24% partial pain relief. Re-irradiation schedules included 20 Gy in 5 fractions in 78% of patients, 8 Gy in a single fraction in 16%, and 30 Gy in 10 fractions in 6%, with a cumulative BED3 range ≈ 58.6–120 Gy3. The mean interval between the first and second courses was 24.8 months (range 6–60). Approximately, 36% of
treatment regimens.
Figure 1: Therapy changes between first diagnosis
Made with FlippingBook - Share PDF online